AbbVie Inc vs Marathon Digital Holdings Inc — how do they compare? AbbVie Inc trades at $248.25 (market cap $441.94B), while Marathon Digital Holdings Inc trades at $9.71 (market cap $3.74B). The key difference: AbbVie Inc is far larger — about 118.2× Marathon Digital Holdings Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Marathon Digital Holdings Inc pays none. Which is the better fit depends on your goals.
| ABBV | MARA | |
|---|---|---|
Market Cap | $441.94B | $3.74B |
Sector | Health | Technology |
52-Week High | $263.58 | $22.84 |
52-Week Low | $197.38 | $6.73 |
Enterprise Value | $506.19B | $5.78B |
Dividend Yield | 2.77% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Marathon Digital Holdings (MARA) trades at $9.95, up 4.08% today but remains under pressure with a bearish technical signal. The company reported a Q2 2026 net loss of $1.60 per share, missing estimates, as revenue fell to $804 million with a net income margin of -429.71%. Despite negative cash flow from operations, MARA is pivoting toward AI digital infrastructure, appointing new directors to support growth. Analyst consensus is mixed with a $16.08 price target but high volatility persists.
MARA's outlook is challenged by persistent losses and high execution risk in its strategic shift, though its low P/E of 3.37 suggests deep value if the AI pivot succeeds. Key risks include Bitcoin price sensitivity, competitive pressures, and cash burn. Investors should weigh the 50% buy rating against fundamental weaknesses before considering a position.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →